Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
about
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.Cancer and inflammation.Cancer Manipulation of Host Physiology: Lessons from Pancreatic Cancer.Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy.Epithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice.Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8(+) T cell number and tumour growth in pancreatic cancer.Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma.TUMOR CROSSTALK NETWORKS PROMOTE GROWTH AND SUPPORT IMMUNE EVASION IN PANCREATIC CANCER.Strategies for Increasing Pancreatic Tumor Immunogenicity.CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?Immunomodulatory Function of Myeloid-Derived Suppressor Cells during B Cell-Mediated Immune Responses.Metabolomics based predictive classifier for early detection of pancreatic ductal adenocarcinoma.Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
P2860
Q37690136-CFFF18E5-9FC5-40BB-BD7D-316DFE06414FQ38711929-EBFD6973-6CE5-40BF-BF51-B790B48E03FDQ39036378-EAEEC888-1D69-4484-80DA-4D1828D6E781Q39235761-31F7F6A9-C769-4FFB-92DA-93DAB6671FFCQ39390859-9C41A4A0-2409-4FE1-B947-FE58C260F2B9Q42325128-F74CF36D-E0FC-4D2F-9444-5509E08C0FEBQ47121552-E62FC24D-A32E-4E61-A710-6F2B8D5B2CA2Q47793665-DF0855A8-696C-4458-ACE4-97E0E5BDA243Q48251095-3E15ECE7-DCBD-4E9B-AE56-0482197FFB83Q49788157-D4BA296A-2626-4CAC-AEC2-943FC15DE960Q52354472-458F2A07-C329-48A0-AE36-DE694D08052BQ52691832-9ED61D86-8B76-4EDA-9E66-9536862A5179Q53069544-1A19F280-C4DB-464B-B3AF-BF7CF9BE8E79Q55240544-4610FA50-24DD-4163-A329-B281AC1C20B6Q55360009-CE603F19-530F-4CA1-BB9D-10F4E6B0AE33Q55445091-0BC9D006-43A0-4A17-8029-4DB3AB31D554Q56890107-D1E86195-FC02-4E18-A3BB-094B6AEB654D
P2860
Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Myeloid cells are required for ...... vironment in pancreatic cancer
@en
Myeloid cells are required for ...... ironment in pancreatic cancer.
@nl
type
label
Myeloid cells are required for ...... vironment in pancreatic cancer
@en
Myeloid cells are required for ...... ironment in pancreatic cancer.
@nl
prefLabel
Myeloid cells are required for ...... vironment in pancreatic cancer
@en
Myeloid cells are required for ...... ironment in pancreatic cancer.
@nl
P2093
P2860
P1433
P1476
Myeloid cells are required for ...... vironment in pancreatic cancer
@en
P2093
Andrew D Rhim
Ashley Velez-Delgado
Diane M Simeone
Dongjun Li
Esha Mathew
Flor M Mendez
Kevin Flannagan
Marina Pasca di Magliano
Yaqing Zhang
P2860
P304
P356
10.1136/GUTJNL-2016-312078
P407
P577
2016-07-08T00:00:00Z